NasdaqGM:GPCRPharmaceuticals
Structure Therapeutics ADA Data Could Reframe Oral Obesity And Diabetes Prospects
Structure Therapeutics (NasdaqGM:GPCR) plans multiple presentations at the 86th American Diabetes Association Scientific Sessions.
The company will share new safety, efficacy, and dosing data for its oral GLP-1 receptor agonist aleniglipron.
Additional data will cover a novel amylin receptor agonist combination, including findings on weight loss effects.
The presentations focus on combination approaches in obesity and diabetes treatment development.
Structure Therapeutics focuses on oral...